Engineering CAR-T Cells: A New Navigation System for Treating Lymphoma

Researchers have developed a method to enhance Chimeric Antigen Receptor (CAR-T) cell therapy by engineering immune cells to express the CCR7 receptor. This modification improves the ability of CAR-T cells to migrate into lymph nodes and increases their efficacy in killing lymphoma cells, according to a study published in Cancer Immunology Research.

Why CAR-T Therapy Struggles with Lymphoma

CAR-T cell therapy has become a transformative treatment for many blood cancers, but it often faces significant hurdles when targeting lymphomas. These cancers frequently reside within lymph nodes, which can be difficult for standard CAR-T cells to reach.

According to Dr. Uta Höpken, group leader of the Microenvironmental Regulation in Autoimmunity and Cancer lab at the Max Delbrück Center, the manufacturing process for conventional CAR-T cells often results in a reduced expression of the CCR7 receptor. This receptor acts as a natural navigation system for immune cells, guiding them into lymph node tissue. Without sufficient CCR7, these therapeutic cells may fail to reach the primary sites of the tumor.

How the CCR7 Modification Improves Treatment

To address this navigation failure, researchers at the Max Delbrück Center, including Dr. Maria Zschummel, engineered CAR-T cells to permanently express the CCR7 receptor. By restoring this receptor, the team aimed to improve the “homing” ability of the cells.

In experiments involving human immune cells, lymphoma cell lines, and mouse models, the researchers observed two critical improvements:

• Enhanced Migration: The modified CAR-T-CCR7 cells successfully migrated into lymph nodes and accumulated there more efficiently than conventional cells.
• Increased Cytotoxicity: The researchers found that the CCR7 modification did more than just improve navigation; it also boosted the cells’ ability to kill lymphoma cells.

Dr. Zschummel, who is now a postdoctoral researcher at Massachusetts General Hospital, noted that the boost in killing efficiency was an unexpected but welcome finding in their study, which was published in the June 2026 issue of Cancer Immunology Research (DOI: 10.1158/2326-6066.cir-25-1381).

Future Implications for Cancer Immunotherapy

The ability to refine the navigation system of immune cells could have broad applications beyond B-cell lymphoma. Dr. Höpken suggests that this strategy might be applied to other types of cancer that spread to lymph nodes, potentially reducing the incidence of relapse by ensuring that therapeutic cells reach the cancer’s primary growth sites.

While the results in preclinical models are promising, the research team emphasizes that this approach is not yet ready for clinical use. Further studies are required to evaluate the safety and long-term effects of using CCR7-engineered cells in human patients. This research underscores how basic immunological insights are critical to developing the next generation of more effective, targeted cell therapies.